EP0951559A1 - Recombinant pox virus for immunization against tumor-associated antigens - Google Patents

Recombinant pox virus for immunization against tumor-associated antigens

Info

Publication number
EP0951559A1
EP0951559A1 EP97933544A EP97933544A EP0951559A1 EP 0951559 A1 EP0951559 A1 EP 0951559A1 EP 97933544 A EP97933544 A EP 97933544A EP 97933544 A EP97933544 A EP 97933544A EP 0951559 A1 EP0951559 A1 EP 0951559A1
Authority
EP
European Patent Office
Prior art keywords
recombinant
virus
gene
pox virus
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97933544A
Other languages
German (de)
English (en)
French (fr)
Inventor
Steven A. Rosenberg
Nicholas Restifo
Dennis L. Panicali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Therion Biologics Corp
US Government
Original Assignee
US Department of Health and Human Services
Therion Biologics Corp
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Therion Biologics Corp, US Government filed Critical US Department of Health and Human Services
Publication of EP0951559A1 publication Critical patent/EP0951559A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Definitions

  • TAAs tumor-associated antigens
  • These antigens which include viral tumor antigens, cellular oncogene proteins, and tumor-associated differentiation antigens, can serve as targets for the host immune system and elicit responses which result in tumor destruction.
  • This immune response is mediated primarily by lymphocytes; T cells in general and class I MHC-restricted cytotoxic T lymphocytes in particular play a central role in tumor rejection.
  • MART-1 Melanoma Antigen Recognized by T cells - 1
  • gp100 Two such antigens have been designated MART-1 (Melanoma Antigen Recognized by T cells - 1 ) and gp100. Proc. Natl. Acad. Sci. U.S.A. 91 :351 5-3519. MART-1 and gp 100 appear to be expressed in virtually all fresh and cultured melanomas. With the exception of melanocyte and retina, no normal tissues express the antigens. The antigens may be responsible for mediating tumor regression in patients with advanced melanoma, since the tumor-infiltrating lymphocytes (TIL) used to identify MART-1 and gp100 were capable of effecting tumor regression in vivo. Thus, immunization of melanoma patients with MART-1 or gp100 may boost their cellular immune responses against their cancers.
  • TIL tumor-infiltrating lymphocytes
  • CEA carcinoembryonic antigen
  • Pox viruses of the family Poxviridae (pox viruses) are useful as vectors for the delivery of foreign genes and gene products in many clinical and research settings.
  • Pox viruses of the genus Orthopoxvirus, particularly vaccinia are used for several reasons. Among these are: (a) its wide use in humans in the eradication of smallpox; (b) its ability to infect a wide range of cells, including professional antigen presenting cells, and express the inserted gene product (i.e. foreign gene product) in a manner that has the potential to be processed in the context of class I and/or class II MHC molecules; and (c) use as a recombinant vaccine in the treatment of certain tumors (Kantor, J. et al. ( 1 992)).
  • Fowlpox vii us is a member of the avipox virus family. Productive FPV infection is restricted in vivo to cells derived from avian species; however, FPV-mediated gene expression does occur in infected non-avian cells. Taylor, J. et al., (1 988) Vaccine 6:497-503.
  • Fowlpox virus based recombinant vaccines are described in: Technological Advances in Vaccine Development (Alan R. Liss, Inc.) pp. 321 -334. Furthermore, in vivo FPV-mediated gene expression in several mammalian species has been demonstrated. Six non-avian species immunized with live recombinant fowlpox virus expressing the rabies glycoprotein developed antibodies against this glycoprotein. Immunization with this recombinant FPV elicited antibodies against this glycoprotein. Immunization with this recombinant FPV partially protected mice, cats, and dogs against a rabies virus challenge.
  • the present invention relates to recombinant pox viruses capable of expressing cell-encoded tumor associated antigens and/or immunomodulators.
  • Recombinant pox virus capable of expressing a cell-encoded tumor-associated antigen are produced by integrating into the pox virus genome sequences encoding the antigen or immunogenic portions thereof.
  • Tumor associated antigens include molecules expressed by tumor cells (e.g. carcinoembryonic antigen, prostate-specific antigen
  • Immunomodulators include interleukin 2, B7.1 and B7.2.
  • Particularly preferred recombinant pox viruses include rV-MART- 1 (vaccinia, MART-1 ), rF-MART-1 (fowlpox, MART-1 ), rV-gp100
  • Figure 1 is a plasmid map of pT2055, the donor plasmid used in the construction of rF-MART-1 .
  • Figure 2 is a plasmid map of pT2054, the donor plasmid used in the construction of rV-MART-1 .
  • Figure 3 is a plasmid map of pT2058, the donor plasmid used in the construction of rV-gp100.
  • Figure 4 is a plasmid map of pT2057, the donor plasmid used in the construction of rF-gp100.
  • Figure 5 is a plasmid map of pT4048, the donor plasmid used in the construction of rV-gp100/IL-2.
  • Figure 6 is a plasmid map of pT2077, the donor plasmid used in the construction of rF-gp100/IL-2.
  • Pox viruses serve as effective vectors for inducing immunity against tumor-associated antigens.
  • tumor-associated antigens are cell surface molecules. These are positioned for recognition by elements of the immune systems and thus are excellent targets for immunotherapy.
  • Tumor-associated antigens are expressed by certain tumor cells and provide effective targets for immunotherapy. Some examples are carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and melanoma specific antigens.
  • Immunomodulators can regulate immune responses, increasing the likelihood of a sufficient cellular immune response occurring, (e.g. IL-2) or can provide cellular ligand necessary for stimulating a CTL response (e.g. B7.1 or B7.2)
  • Patent No. 5,093,258 the disclosure of which is incorporated herein by reference.
  • Other techniques include using a unique restriction endonuclease site that is naturally present or artificially inserted in the parental viral vector to insert the heterologous DNA. See, U.S. Patent No. 5,445,953, incorporated herein by reference.
  • Pox viruses useful in practicing the present invention include orthopox, suipox, avipox and capripoxvirus.
  • Orthopox virus include vaccinia, ectromelia and raccoon pox.
  • the preferred orthopox is vaccinia. More preferred is a sub-clone of vaccinia having decreased virulence relative to a standard vaccine strain of vaccinia.
  • Avipox viruses include fowlpox, canary pox and pigeon pox.
  • the preferred avipox is fowlpox.
  • a preferred suipox is swinepox.
  • the DNA gene sequence to be inserted into the virus can be placed into a donor plasmid, e.g., an E. coli plasmid construct.
  • a donor plasmid e.g., an E. coli plasmid construct.
  • the DNA gene sequence to be inserted is ligated to a promoter.
  • the promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA which is the desired insertion region.
  • a pox promoter is used with a parental pox viral vector.
  • the resulting plasmid construct is then amplified by growth within E. coli bacteria and isolated.
  • the plasmid also contains an origin of replication such as the E. coli origin of replication, and a marker such as an antibiotic resistance gene for selection and propagation in E. coli.
  • the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g., chick embryo fibroblasts, along with the parental virus, e.g., poxvirus.
  • a cell culture e.g., chick embryo fibroblasts
  • the parental virus e.g., poxvirus.
  • Recombination between homologous pox DNA in the plasmid and the viral genome respectively results in a recombinant poxvirus modified by the presence of the promoter-gene construct in its genome, at a site which does not affect virus viability.
  • the gene is inserted into a region (insertion region), in the virus which does not affect virus viability of the resultant recombinant virus.
  • a region insertion region
  • the skilled artisan can readily identify such regions in a virus by, for example, randomly testing segments of virus DNA for regions that allow recombinant formation without seriously affecting virus viability of the recombinant.
  • One region that can readily be used and is present in many viruses is the thymidine kinase (TK) gene.
  • TK thymidine kinase
  • the TK gene has been found in all pox virus genomes examined [leporipoxvirus: Upton, et al., J. Virology, 60:920 (1 986)
  • insertion regions include, for example, Hindlll M.
  • insertion regions include, for example, BamHI J [Jenkins, et al., AIDS Research and Human Retroviruses 7:991 -998 (1 991 )] the £coRI-/V//7_/lll fragment, BamYW fragment, EcoR ⁇ /-Hind ⁇ fragment, BamH ⁇ fragment and the Hind ⁇ fragment set forth in EPO Application No. 0 308 220 A1 .
  • BamHI J Jenkins, et al., AIDS Research and Human Retroviruses 7:991 -998 (1 991 )
  • the £coRI-/V//7_/lll fragment BamYW fragment
  • EcoR ⁇ /-Hind ⁇ fragment BamH ⁇ fragment
  • Hind ⁇ fragment set forth in EPO Application No. 0 308 220 A1 .
  • preferred insertion sites include the thymidine kinase gene region.
  • the promoter must be placed so that it is located upstream from the gene to be expressed. Promoters are well known in the art and can readily be selected depending on the host and the cell type you wish to target. For example in poxviruses, pox viral promoters should be used, such as the vaccinia 7.5K, or 40K or fowlpox C1 . Artificial constructs containing appropriate pox sequences can also be used. Enhancer elements can also be used in combination to increase the level of expression. Furthermore, the use of inducible promoters, which are also well known in the art, are preferred in some embodiments.
  • Live recombinant viruses expressing an immunogenic cell encoded tumor associated antigen can be used to induce an immune response against tumor cells which express the protein.
  • These recombinant viruses may be administered by intradermal scarification, as was conventionally done for small pox vaccination, or by other routes appropriate to the recombinant virus used. These may include among others, intramuscular, subcutaneous, and intravenous routes. Vaccination of a host organism with live recombinant vaccinia virus is followed by replication of the virus within the host.
  • the recombinant vectors will typically be injected in a sterile aqueous or non-aqueous solution, suspension or emulsion in association with a pharmaceutically- acceptable carrier such as physiological saline.
  • a specific immune response to a tumor associated antigen can be generated by administering between about 1 0 5 -1 0 9 pfu of the recombinant pox virus, constructed as discussed above to a host, more preferably one uses _>.1 0 7 pfu.
  • the preferred host is a human.
  • At least one interval thereafter, which is preferably one to three months later, the immune response is boosted by administering additional antigen to the host. More preferably there is at least a second "boost" preferably at least one to three months after the first boost, more preferably 6-12 months after the first boost.
  • the antigen for boosting may be administered using the same pox virus vector.
  • the boosting antigen may be administered as a whole protein, an immunogenic peptide fraction of the protein, or DNA encoding the protein or peptide.
  • the boosting antigen may preferably be administered using a second pox virus vector from a different pox genus, or may be administered directly, for example, purified protein plus an adjuvant or in a liposome formation.
  • Cytokines e.g., IL-2, IL-6, IL-1 2, IL-1 5, or co-stimulatory molecules, e.g., B7.1 , B7.2, may be used as biologic adjuvants.
  • the cytokines can be administered systemically to the host, either cytokines or costimulatory molecules can be co-administered via insertion of the genes encoding the molecules into the recombinant pox vector or a second recombinant poxvirus which is admixed with the recombinant poxvirus expressing the TAA.
  • Adjuvants include, for example, RIBI Detox (Ribi
  • Cytotoxic T-cells specific for a tumor specific antigen can be established from peripheral blood mononuclear cells (PBMC) obtained from a host immunized as discussed above.
  • PBMC peripheral blood mononuclear cells
  • PBMC can be separated by using Lymphocyte Separation Medium gradient (Organon Teknika, Durham, NC, USA) as previously described [Boyum, et al., Scand J. Clin Lab Invest 21 : 77-80 (1 968)].
  • Washed PBMC are resuspended in a complete medium, for example, RPMI 1 640 (GIBCO) supplemented with 10% pool human AB serum (Pel-Freeze Clinical System, Brown Dear, Wl, USA), 2mM glutamine, 1 00 U/ml penicillin and 100 ⁇ g/ml of streptomycin (GIBCO) .
  • PBMC at a concentration of about 2 x 1 0 5 cells in complete medium in a volume of, for example, 100 ⁇ are added into each well of a 96-well flat-bottom assay plate (Costar, Cambridge, MA, USA).
  • the antigen or peptides are added into the cultures in a final concentration of about 50 ⁇ glmi and incubated at 37°C in a humidified atmosphere containing 5% CO 2 for 5 days. After removal of peptide containing media, the cultures are provided with fresh human IL-2 (10U/ml) after 5 days and replenished with IL-2 containing medium every 3 days. Primary cultures are restimulated with the same peptide (50 ⁇ g/ml) on day 1 6. 5 x 10 5 irradiated (4,000 rad) autologous PBMC are added in a volume of about 50 ⁇ complete medium as antigen-presenting cells (APC) . About five days later, the cultures are provided with human IL-2 containing medium as described previously. Cells are restimulated for 5 days at intervals of 1 6 days.
  • the cytotoxic T-cell can be cultured to amplify its number and then injected back into the host by a variety of means. Generally, between 1 x 10 5 and 2 x 10" cytotoxic T-cells per infusion are administered in, for example, one to three infusions of 200 to 250 ml each over a period of 30 to 60 minutes. After the completion of the infusions, the patient may be treated with recombinant interleukin-2 with a dose of 720,000 IU per kilogram of body weight intravenously every eight hours; some doses can be omitted depending on the patient's tolerance for the drug.
  • additional antigen or fragments containing T-cell eliciting epitope(s) may be administered to the patient to further expand the T-cell number.
  • the antigen or epitope may be formulated with an adjuvant and/or may be in a liposomal formulation.
  • the cytotoxic T-cells can also be modified by introduction of a viral vector containing a DNA encoding TNF and reintroduced into a host in an effort to enhance the anti-tumor activity of the cells.
  • Other cytokines can also be used.
  • pox viruses have been developed as live viral vectors for the expression of heterologous proteins (Cepko et al., Cell 37: 1 053-1062 (1 984); Morin et al., Proc. Natl. Acad. Sci. USA 84:4626-4630 ( 1 987); Lowe et al., Proc. Natl. Acad. Sci. USA, 84:3896-3900 (1987); Panicali & Paoletti, Proc. Natl. Acad. Sci. USA,
  • the parental fowlpox virus is a plaque purified isolate of the POXVAC-TC vaccine strain of fowlpox virus (Schering Corp.).
  • the parental vaccinia virus (clone B-3-1 ) is a plaque-purified isolate of the Wyeth strain that was received from Flow Laboratories.
  • the Wyeth strain of vaccinia was passaged in the fetal rhesus lung line FRhL (ATCC Accession No. CL1 60) as follows: Pass 1 : Plaque "B” was picked at 1 0- 5 3 dilution Pass 2: Plaque "B-3” was picked at 1 0- 1 6 dilution Pass 3: Plaque "B-3-1 " was picked at 10- 1 6 dilution Pass 4-7: Plaque B-3-1 was serially passaged using serum-free medium with sucrose phosphate glutamate (SPG) to prepare a small seed pool at the 7th passage level.
  • SPG sucrose phosphate glutamate
  • the virulence of this plaque isolate of the Wyeth vaccinia strain was assessed by determining the infections dose of the virus lethal to
  • mice 50% (LD 50 ) of weaning mice infected intracranially.
  • LD 50 50% (LD 50 ) of weaning mice infected intracranially.
  • Two to three week old immunocompetent mice were inoculated with various doses of virus (7 mice/dose); the LD 50 was determined on mice succubing between 2 and 12 days post-inoculation by calculating the 50% endpoint using the Reed-Muench method (20). These values were compared to those obtained using a virus stock prepared by expanding virus directly from a vial of the CDC Smallpox Vaccine (Table 1 ).
  • Genes that code for desired carcinoma associated antigens are inserted into the genome of a pox virus in such a manner as to allow them to be expressed by that virus along with the expression of the normal complement of parent virus proteins. This can be accomplished by first constructing a DNA donor vector for in vivo recombination with a pox virus.
  • the DNA donor vector contains the following elements:
  • a prokaryotic origin of replication so that the vector may be amplified in a prokaryotic host
  • a gene encoding a marker which allows selection of prokaryotic host cells that contain the vector e.g., a gene encoding antibiotic resistance
  • at least one gene encoding a desired protein located adjacent to a transcriptional promoter capable of directing the expression of the gene e.g., DNA sequences homologous to the region of the parent virus genome where the foreign gene(s) will be inserted, flanking the construct of element (iii).
  • donor plasmids for the introduction of multiple foreign genes into pox virus are described in W091 /1 9803, the techniques of which are incorporated herein by reference.
  • all DNA fragments for construction of the donor vector including fragments containing transcriptional promoters and fragments containing sequences homologous to the region of the parent virus genome into which foreign genes are to be inserted, can be obtained from genomic DNA or cloned DNA fragments.
  • the donor plasmids can be mono-,di-, or multivalent (i.e., can contain one or more inserted foreign gene sequences) .
  • the donor vector preferably contains an additional gene which encodes a marker which will allow identification of recombinant viruses containing inserted foreign DNA.
  • a marker which will allow identification of recombinant viruses containing inserted foreign DNA.
  • Several types of marker genes can be used to permit the identification and isolation of recombinant viruses.
  • genes that encode antibiotic or chemical resistance include genes that encode antibiotic or chemical resistance (e.g., see Spyropoulos et al., J. Virol. , 62: 1046 (1988); Falkner and Moss., J. Virol. , 62: 1 849 (1 988); Franke et al., Mol. Cell. Bio/. , 5: 191 8 ( 1 985), as well as genes such as the E. coli lacZ gene, that permit identification of recombinant viral plaques by coiorimetric assay
  • host cells for in vivo recombination are generally eukaryotic cells that can be infected by the virus and transfected by the plasmid vector.
  • Examples of such cells suitable for use with a pox virus are chick embryo dermal (CED) cells, HuTK1 3 (human) ceils, and CV-1 and BSC-40 (both monkey kidney) cells. Infection of cells with pox virus and transfection of these cells with plasmid vectors is accomplished by techniques standard in the art (Panicali and Paoletti, U.S. Patent No. 4,603, 1 1 2,
  • recombinant viral progeny can be identified by one of several techniques. For example, if the DNA donor vector is designed to insert foreign genes into the parent virus thymidine kinase (TK) gene, viruses containing integrated DNA will be TK " and can be selected on this basis (Mackett et al., Proc. Natl. Acad. Sci. USA, 79:741 5 ( 1 982)) . Alternatively, co-integration of a gene encoding a marker or indicator gene with the foreign gene(s) of interest, as described above, can be used to identify recombinant progeny.
  • One preferred indicator gene is the E. coli lacZ gene: recombinant viruses expressing ⁇ -galactosidase can be selected using a chromogenic substrate for the enzyme (Panicali et al., Gene, 47: 1 93 (1986)).
  • recombinant viral progeny can be identified by one of several techniques.
  • the presence of integrated foreign DNA can be detected by hybridization with a labeled DNA probe specific for the inserted DNA.
  • Preferred techniques for selection are based upon co-integration of a gene encoding a marker or indicator gene along with the gene of interest, as described above.
  • a preferred indicator gene is the E. coli lacZ gene which encodes the enzyme ⁇ -galactosidase.
  • Selection of recombinant virus expressing ⁇ - galactosidase can be done by employing a chromogenic substrate for the enzyme.
  • recombinant viruses are detected as blue plaques in the presence of the substrate 5-bromo-4-chloro-3-indolyl- ⁇ - D-galactoside or other halogenated-indolyl- ⁇ -D-galactoside (e.g., BluoGalTM).
  • black plaque assay an in situ enzyme immunoassay performed on viral plaques
  • Western blot analysis a variety of methods can be used to assay the expression of the polypeptide encoded by the inserted gene.
  • RIPA radioimmunoprecipitation
  • EIA enzyme immunoassay
  • This vector contains the following elements: ( 1 ) a prokaryotic origin of replication to allow amplification of the vector in a bacterial host; (2) the gene encoding resistance to the antibiotic ampicillin, to permit selection of prokaryotic host cells that contain the plasmid; (3) DNA sequences homologous to the Hindlll M region of the vaccinia genome, which direct insertion of foreign sequences into this region via homologous recombination; (4) a chimeric gene comprising the vaccinia 40K transcriptional promotor linked to the gpl OO gene; (5) a second chimeric gene comprising the fowlpox C1 transcriptional promoter linked to the E. coli lacZ gene.
  • a plaque-purified isolate from the Wyeth (New York City Board of Health) strain of vaccinia was used as the parental virus in the construction of the recombinant vaccinia virus, rV-gp100.
  • the generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the Wyeth vaccinia genome and the corresponding sequences in pT2058 in vaccinia-infected RK 13 cells (CCL 37, ATCC) transfected with pT2058.
  • Recombinant virus was identified using a chromogenic assay, performed on viral plaques in situ, that detects expression of the lacZ gene product in the presence of halogenated indolyl-beta-D-galactoside (Bluo-gal), as described previously (Panacali, et al., 1986) .
  • Appropriate blue recombinant viruses were purified by four rounds of plaque- purification.
  • Virus stocks were prepared by clarifying infected RK 13 cell lysates followed by centrifugation through a 36% sucrose cushion.
  • the generation of recombinant fowlpox viruses is accomplished via homologous recombination in vivo between fowlpox DNA and a plasmid vector that carries the heterologous sequences to be inserted.
  • the plasmid vectors contain one or more chimeric genes, each comprising a poxvirus promoter linked to a protein coding sequence, flanked by viral sequences from a non-essential region of the fowlpox virus genome.
  • the plasmid is transfected into cells infected with the parental fowlpox virus, and recombination between fowlpox sequences on the plasmid and the corresponding DNA in the viral genome results in the insertion into the viral genome of the chimeric genes on the plasmid.
  • the plasmid vector (pT2055) used for insertion of the MART-1 gene into the parental fowlpox virus genome by in vivo recombination is illustrated in Figure 1 .
  • This vector contains the following elements: (1 ) a prokaryotic origin of replication to allow amplification of the vector in a bacterial host; (2) the gene encoding resistance to the antibiotic ampicillin, to permit selection of prokaryotic host cells that contain the plasmid; (3) DNA sequences homologous to the BamHIJ region of the fowlpox genome, which direct insertion of foreign sequences into this region via homologous recombination; (4) a chimeric gene comprising the vaccinia 40K transcriptional promotor linked to the MART-1 gene; (5) a second chimeric gene comprising the fowlpox C1 transcriptional promoter linked to the E. coli lacZ gene.
  • MART-1 The gene encoding MART-1 was isolated at the National Cancer Institute from a cDNA library derived from RNA from the HLA-A2 + melanoma cell line 501 mel. Kawakami, Y., et al., ( 1994) Proc. Natl. Acad. Sci. U.S.A. 91 :3515-351 9.
  • a plaque-purified isolate from the POXVAC-TC vaccine strain of fowlpox virus was used as the parental virus for this recombinant vaccine.
  • In vivo recombination between the plasmid vector and the viral DNA resulted in the formation of a recombinant virus in which the MART-1 gene, under the transcriptional direction of the vaccinia 40K promoter, and the lacZ gene, under the control of the C1 promoter, were inserted into the BamHIJ region of the fowlpox virus genome.
  • a chromogenic assay for ⁇ -galactosidase was used to identify recombinant viruses containing the lacZ and MART-1 sequences. This method takes advantage of the ability of fowlpox virus to form distinct plaques when grown on monolayers of CED cells. After in vivo recombination, cells were infected with progeny virus until distinct plaques were visible, at which time the plaques were overlaid with a chromogenic substrate for Beta-gaiactosidase (Bluo-gal). Viral plaques expressing lacZ appeared blue against a clear background. Positive plaques were picked from the cell monolayer and their progeny were further propagated.
  • Beta-gaiactosidase Beta-gaiactosidase
  • the structure of the plasmid transfer vector was verified by restriction endonuclease digestion using Xba I and BamHI.
  • the products of digestion with these enzymes were subjected to Southern blot analysis using labeled probes corresponding to the MART-1 gene and to the fowlpox BamHI J sequences.
  • the DNA fragments visualized by these methods were of the predicted sizes, and the presence of the MART-1 gene was unequivocally demonstrated, thus confirming the predicted structure of the plasmid.
  • the recombinant pox virus set forth below in Table 2 can be constructed using similar techniques.
  • IL-2 rV-gp1 00/IL-2 pT4048 gp100 + IL-2 (gpl OO rF-gp100/IL-2 pT2077 gp1 00 + IL-2 above) IL-2:
EP97933544A 1996-07-25 1997-07-09 Recombinant pox virus for immunization against tumor-associated antigens Withdrawn EP0951559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68628196A 1996-07-25 1996-07-25
US686281 1996-07-25
PCT/US1997/012546 WO1998004728A1 (en) 1996-07-25 1997-07-09 Recombinant pox virus for immunization against tumor-associated antigens

Publications (1)

Publication Number Publication Date
EP0951559A1 true EP0951559A1 (en) 1999-10-27

Family

ID=24755677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97933544A Withdrawn EP0951559A1 (en) 1996-07-25 1997-07-09 Recombinant pox virus for immunization against tumor-associated antigens

Country Status (5)

Country Link
EP (1) EP0951559A1 (ja)
JP (1) JP2000515759A (ja)
AU (1) AU718945B2 (ja)
CA (1) CA2261990A1 (ja)
WO (1) WO1998004728A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2000020027A2 (en) * 1998-10-05 2000-04-13 M & E Biotech A/S Methods for therapeutic vaccination
JP4540033B2 (ja) * 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2467486A1 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
AU2004280608B2 (en) 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3907698B2 (ja) * 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9804728A1 *

Also Published As

Publication number Publication date
CA2261990A1 (en) 1998-02-05
AU3670697A (en) 1998-02-20
WO1998004728A1 (en) 1998-02-05
AU718945B2 (en) 2000-05-04
JP2000515759A (ja) 2000-11-28

Similar Documents

Publication Publication Date Title
US7410644B2 (en) Recombinant pox virus for immunization against tumor-associated antigens
US7118738B2 (en) Recombinant pox virus for immunization against MUC1 tumor-associated antigen
AU774076B2 (en) A recombinant vector expressing multiple costimulatory molecules and uses thereof
US6969609B1 (en) Recombinant vector expressing multiple costimulatory molecules and uses thereof
AU712714B2 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
AU718945B2 (en) Recombinant pox virus for immunization against tumor-associated antigens
CA2252406A1 (en) Heterologous boosting immunizations
US20050100558A1 (en) Heterologous boosting immunizations
AU767562B2 (en) Recombinant pox virus for immunization against tumor-associated antigens
AU2003266471A1 (en) Recombinant pox virus for immunization against tumor-associated antigens
EP1865065A1 (en) A recombinant vector expressing multiple costimulatory molecules and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PANICALI, DENNIS, L.

Inventor name: RESTIFO, NICHOLAS

Inventor name: ROSENBERG, STEVEN, A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20011102